上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (6): 806-.doi: 10.3969/j.issn.1674-8115.2011.06.027

• 论著（临床研究） • 上一篇    下一篇

阿托伐他汀对不稳定性心绞痛患者血清sRAGE和esRAGE水平的影响

李若谷, 方唯一, 曲新凯, 陈 晖, 杨栓锁, 沙慧芳, 关韶峰   

  1. 上海交通大学附属胸科医院心内科, 上海 200030
  • 出版日期:2011-06-28 发布日期:2011-06-27
  • 通讯作者: 方唯一, 电子信箱: fwychest@163.com。
  • 作者简介:李若谷（1976—）, 女, 主治医师, 博士；电子信箱: liruogu@hotmail.com。

Effects of atorvastatin on serum levels of sRAGE and esRAGE in patients with unstable angina

LI Ruo-gu, FANG Wei-yi, QU Xin-kai, CHEN Hui, YANG Shuan-suo, SHA Hui-fang, GUAN Shao-feng   

  1. Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, China
  • Online:2011-06-28 Published:2011-06-27

PDF (PC)

1483

摘要：

目的 探讨阿托伐他汀对不稳定性心绞痛患者血清可溶性晚期糖基化终产物受体(SRAGE)和内源性分泌型晚期糖基化终产物受体（esRAGE）水平的影响。方法 不稳定性心绞痛患者40例（UA组），给予阿托伐他汀20 mg口服，每日1次，于治疗前和治疗后3个月分别采集静脉血，测量血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白-胆固醇（LDL-C）、高密度脂蛋白-胆固醇（HDL-C）、血糖、糖化血红蛋白（HbA1C）、sRAGE及esRAGE水平。另选择20名年龄、性别相匹配的健康体检者作为正常对照组。结果 治疗前，UA组的TC和LDL-C水平显著高于正常对照组（P<0.05），sRAGE和esRAGE水平显著低于正常对照组（P<0.05，P<0.01），两组其他指标比较差异均无统计学意义（P>0.05）。经阿托伐他汀治疗3个月后，UA组患者的血糖和HbA1C水平无明显变化（P>0.05），但TC和LDL-C水平明显低于治疗前（P<0.05），sRAGE和esRAGE水平明显高于治疗前（P<0.05）；直线相关分析显示，esRAGE水平与LDL-C浓度呈负相关（r=-0.36，P=0.01）。结论 他汀类药物具有多效性，阿托伐他汀能升高不稳定性心绞痛患者血清sRAGE和esRAGE水平。

关键词: 阿托伐他汀, 不稳定性心绞痛, 可溶性晚期糖基化终产物受体, 内源性分泌型晚期糖基化终产物受体

Abstract:

Objective To investigate the effects of atorvastatin on serum levels of soluble receptor for advanced glycation end products(sRAGE) and endogenous secretory receptor for advanced glycation end products(esRAGE) in patients with unstable angina. Methods Forty patients with unstable angina (UA group) were selected, and 20 mg/d of atorvastatin was orally administrated. Venous blood samples were obtained before treatment and 3 months after treatment, and serum total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol(HDL-C), glucose, glycated hemoglobin(HbA1C), sRAGE and esRAGE were measured. Another 20 age and gender matched healthy subjects were served as control group. Results Before treatment, serum levels of TC and LDL-C in UA group were significantly higher than those in control group (P<0.05), and serum levels of sRAGE and esRAGE in UA group were significantly lower than those in control group (P<0.05, P<0.01), while there was no significant difference in the other parameters between groups (P>0.05). After treatment with atorvastatin for 3 months, serum levels of glucose and HbA1C in UA group were not significantly different from those before treatment (P>0.05), serum levels of TC and LDL-C were significantly lower than those before treatment （P<0.05), and serum levels of sRAGE and esRAGE were significantly higher than those before treatment (P<0.05). Linear correlation analysis revealed that there was a negative correlation between serum level of esRAGE and serum level of LDL-C （r=－0.36，P=0.01）. Conclusion Statins have pleiotropic effects, and atorvastatin can increase serum levels of sRAGE and esRAGE in patients with unstable angina.

Key words: atorvastatin, unstable angina, soluble receptor for advanced glycation end products, endogenous secretory receptor for advanced glycation end products